Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 285,66 € (-4,25 %). Medianen er 300,53 € (+0,73 %).
| Køb |
28 |
| Behold |
9 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Charles River Laboratories as key partner for FDA approvals in the preclinical phase
Charles River Laboratories was involved in more than 80% of the drugs recently approved by the FDA in the preclinical phase and is therefore regarded as a central service provider for early drug development. Its business model combines mandatory safety studies with high‑margin, recurring sales of test kits for quality control of sterile pharmaceuticals. The company benefits from increasing outsourcing by Big Pharma and the growth of complex biologics, creating long‑term stable demand and growth opportunities. » Mere på finanzen.net
Charles River sparks rally: AI demand, raised annual targets and cost-cutting program support shares
AI-driven drug discovery boosts demand for laboratory testing, from which Charles River, as a top beneficiary, is profiting. After quarterly results from Danaher and Medpace, investors have been buying more aggressively, putting Charles River at the forefront of the rally. The company reports full order books, has raised its annual targets and launched a cost-saving program; third-quarter results will be the next acid test. » Mere på finanzen.net
Charles River Laboratories bets on digitization with Apollo Orchestrate and sets new long-term targets
Charles River Laboratories aims for annual organic revenue growth of 5–7% for 2027–2030 and an operating margin of around 24%. The new technology Apollo Orchestrate digitizes lab processes from sample submission to release and reduces administrative workload. Automation and paperless quality controls are intended to minimize audit risks and, as structural efficiency drivers, strengthen profitability. » Mere på finanzen.net
Charles River raises 2026 outlook and beats Q2 expectations
Charles River has significantly raised its full-year 2026 guidance and now expects adjusted earnings per share of $11.15 to $11.45 and revenue of up to $3.920 billion, both above the market consensus. In the second quarter the company beat expectations with adjusted EPS of $3.02 and revenue of $1.004 billion. Analysts reacted positively: TD Cowen confirmed its buy rating and raised the price target to $325. » Mere på finanzen.net
Charles River Laboratories sold by Riverwater as fund reallocates to Stevanato Group
Riverwater Partners' Sustainable Value Strategy sold Charles River Laboratories to fund a purchase of Stevanato Group, citing caution about the long-term impact of the FDA's New Approach Methodologies on Charles River's animal testing business. The strategy underperformed the Russell 2500 Value in Q2, driven mainly by stock selection and tech exposure differences. Charles River's shares are up about 81% over the past year and trade within a 52-week range of $144.26 to $303.31. » Mere på finance.yahoo.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 862,75 mio. | 0,48 % |
| Bruttofortjeneste | 314,18 mio. | 8,52 % |
| Nettoresultat | 292,4 mio. | 528,76 % |
| EBITDA | 237,46 mio. | 40,51 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 14,54 mia. € |
Antal aktier | 47,92 mio. |
Højeste/laveste i 52 uger | 345,73 € - 133,14 € |
| Udbytte | Nej |
Beta | 1,34 |
P/E (PE Ratio) | 326,72 |
PEG (PEG Ratio) | -3,67 |
K/I (PB Ratio) | 4,94 |
P/S (PS Ratio) | 4,02 |
Virksomhedsprofil
Charles River Laboratories International, Inc. er en non-klinisk contract research organization, der leverer lægemiddeludvikling, non-klinisk udvikling og sikkerhedstestydelser i USA, Europa, Canada, Asien-Stillehavsregionen og internationalt. Virksomheden opererer gennem tre segmenter: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) og Manufacturing Solutions (Manufacturing). RMS-segmentet producerer og sælger gnavermodelstammer samt specifikt avlede rotter og mus til brug for forskere. Segmentet tilbyder også en række ydelser, der hjælper kunderne med at anvende forskningsmodeller i forskning og screening af non-kliniske lægemiddelkandidater, herunder forskningsmodeller, genetisk modificerede modeller og tilhørende ydelser, insourcing-løsninger og diagnostiske ydelser til forskningsdyr. DSA-segmentet tilbyder tidlige og in vivo-opdagelsesydelser til identifikation og validering af nye targets, kemiske forbindelser og antistoffer gennem levering af non-kliniske lægemiddel- og terapikandidater, der er klar til sikkerhedsvurdering; og sikkerhedsvurderingsydelser, såsom toksikologi, patologi, sikkerhedsfarmakologi, bioanalyse, lægemiddelmetabolisme og farmakokinetik. Manufacturing-segmentet leverer in vitro-metoder til konventionel og hurtig kvalitetskontroltest af sterile og ikke-sterile lægemidler og forbrugerprodukter. Segmentet tilbyder også specialiseret test af biologiske lægemidler, som outsources af farmaceutiske og bioteknologiske virksomheder, samt ydelser inden for fjerfævaccine, der leverer specifikt-patogenfri (SPF) befrugtede høneæg, SPF-høns og diagnostiske produkter, der anvendes til fremstilling af vacciner. Virksomheden leverer også kontraktbaseret drift af vivarier til biofarmaceutiske kunder. Charles River Laboratories International, Inc. blev grundlagt i 1947 og har hovedkontor i Wilmington, Massachusetts.
| Navn | Charles River Labs Intl |
| CEO | Birgit Girshick |
| Hjemsted | Wilmington,
ma USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 23.06.2000 |
| Medarbejdere | 19.000 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | CRL |
Frankfurt | RV6.F |
Düsseldorf | RV6.DU |
SIX | RV6.SW |
München | RV6.MU |